- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| TSCAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.01. | TScan Therapeutics, Inc. - 8-K, Current Report | 7 | SEC Filings | ||
| 06.12.25 | TScan Therapeutics, Inc.: TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition | 134 | GlobeNewswire (Europe) | Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52) 3/3 (100%) of TSC-101-treated patients who reached two-year follow-up... ► Artikel lesen | |
| 04.12.25 | TScan Therapeutics To Provide Update On Phase 1 Trial Of TSC-101 In Heme Malignancies Next Week | 1 | RTTNews | ||
| 03.12.25 | TScan Therapeutics lädt zu KOL-Event über aktualisierte ALLOHA-Studiendaten | 1 | Investing.com Deutsch | ||
| 03.12.25 | TScan Therapeutics, Inc.: TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA Phase 1 Trial and Future Market Opportunities | 2 | GlobeNewswire (USA) | ||
| 26.11.25 | TScan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.11.25 | Morgan Stanley downgrades Tscan Therapeutics stock on delayed trials | 6 | Investing.com | ||
| 12.11.25 | Tscan Therapeutics: EPS übertrifft Schätzungen um 0,06 $ - Umsatz besser als erwartet | 1 | Investing.com Deutsch | ||
| 12.11.25 | TScan Therapeutics, Inc. Q3 Loss Increases, But Beats Estimates | - | RTTNews | ||
| 12.11.25 | TScan Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.11.25 | TScan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.11.25 | BTIG downgrades Tscan Therapeutics stock to Neutral on program delays | 3 | Investing.com | ||
| 03.11.25 | Tscan Therapeutics-Aktie bricht nach Aussetzung einer Studie zu soliden Tumoren ein | 6 | Investing.com Deutsch | ||
| 03.11.25 | TScan lays off 30% of workforce, halts phase 1 solid tumor T-cell receptor trial | 2 | FierceBiotech | ||
| 03.11.25 | TScan to focus on heme program, cuts workforce by 30% amid FDA progress | 5 | Investing.com | ||
| 03.11.25 | TScan Therapeutics, Inc.: TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027 | 361 | GlobeNewswire (Europe) | Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to prioritize... ► Artikel lesen | |
| 03.11.25 | TScan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.09.25 | TScan Therapeutics, Inc.: TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025 | 2 | GlobeNewswire (USA) | ||
| 09.09.25 | TScan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.08.25 | TScan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 95,80 | -0,21 % | Pharma- und Biotech-Aktien 2026: Bayer und BioNTech geben Gas, Bioxyne vor Durchbruch? | ||
| MEDIGENE | 0,046 | -3,39 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
| AMGEN | 288,20 | -0,10 % | Amgen, Kyowa Kirin End Collaboration On Atopic Dermatitis Drug Rocatinlimab | THOUSAND OAKS (dpa-AFX) - Kyowa Kirin Co., Ltd. (KYKOY) said on Friday it has ended its development and commercialization partnership with Amgen for rocatinlimab, with the Japanese drugmaker... ► Artikel lesen | |
| BIOGEN | 149,10 | +1,19 % | Biogen Says FDA Grants Breakthrough Therapy Designation For Litifilimab To Treat CLE | WESTON (dpa-AFX) - Biogen, Inc. (BIIB) announced Wednesday that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for litifilimab (BIIB059) for the treatment... ► Artikel lesen | |
| BIOFRONTERA | 2,440 | 0,00 % | BIOFRONTERA AG - Stabilität als strategisches Signal | ||
| CORE ONE LABS | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 626,80 | +0,16 % | Regeneron Pharmaceuticals Inc Bottom Line Retreats In Q4 | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc (REGN) announced a profit for fourth quarter that Drops, from the same period last yearThe company's earnings totaled $844.6 million, or... ► Artikel lesen | |
| EDITAS MEDICINE | 1,645 | -1,26 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| GALAPAGOS NV | 28,540 | +0,28 % | Galapagos NV: Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities | Mechelen, Belgium; January 5, 2026, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the works council consultation process regarding the wind-down of cell therapy activities has... ► Artikel lesen | |
| IMMATICS | 8,050 | -0,25 % | Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress | IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose levelsEncouraging early clinical anti-tumor... ► Artikel lesen | |
| AUTOLUS THERAPEUTICS | 1,150 | 0,00 % | Autolus Therapeutics plc - 8-K, Current Report | ||
| IGM BIOSCIENCES | 1,080 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 14.08.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 14.08.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 14.08.2025.ISIN NameCA87168M1068 SYNEX... ► Artikel lesen | |
| ONCOPEPTIDES | 0,280 | -4,60 % | Oncopeptides AB: Oncopeptides announces Q4 2025 sales and updates cash-flow expectations | Stockholm, January 15, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the net sales for the fourth quarter of 2025 and... ► Artikel lesen | |
| AVACTA | 0,595 | -1,65 % | AVACTA GROUP PLC: Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION Medicine, FAP-Exatecan (AVA6103) | The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026 LONDON and PHILADELPHIA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company",... ► Artikel lesen | |
| DERMATA THERAPEUTICS | 2,240 | -19,28 % | Dermata Therapeutics, Inc. - 8-K, Current Report |
TSCAN THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -1,44 % bei einem Aktienkurs von 1,025 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TSCAN THERAPEUTICS INC finden Sie auf Wallstreet Online.